Hancock Jaffe Laboratories Incの資本の返還

Hancock Jaffe Laboratories Incの資本の返還は何ですか。

Hancock Jaffe Laboratories Incの資本の返還は-55.76%です。

資本の返還の定義は何ですか。



株主資本利益率は、株主資本の簿価との関係で事業の収益性の尺度です。これは、会計年度純利益を株主資本合計で除算することによって計算されます。

The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.

NASDAQのセクタHealth Careにおける資本の返還の企業と比べるHancock Jaffe Laboratories Inc

Hancock Jaffe Laboratories Incは何をしますか。

Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraftÒ, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.

Hancock Jaffe Laboratories Incと類似の資本の返還